Formononetin acts synergistically with a JAK2 inhibitor to suppress growth in myeloproliferative neoplasm by inhibiting JAK/STAT3 signaling pathway
نویسندگان
چکیده
Purpose: To determine the effect of formononetin (FMNT) in proliferation, drug resistance, and DNA damage myeloproliferative neoplasm (MPN), to evaluate potential FMNT as a therapeutic target.
 Methods: Cell viability curves colony formation assays were used characterize proliferation HEL or HEL/R cells. Flow cytometry was conducted assess apoptosis cells, while western blotting performed expressions H2AX, DNA-PK, Rad51, which are indicative damage, phosphorylation levels JAK2 STAT3 determined.
 Results: Formononetin suppressed cell cells dose-dependent manner. It significantly reduced promoted (p < 0.05). For treatment viability, apoptosis. Moreover, elevated H2AX DNA-PK Rad51 TG101209 (TG)-induced JAK-TKI-resistant Furthermore, decreased JAK- TKI-resistant cells.
 Conclusion: Treatment with represses promotes apoptosis, weakens JAK-TKI strengthens MPN by suppressing JAK/STAT3 pathway. This suggests that is candidate for MPN.
منابع مشابه
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation events as MPL, TET2, LNK, EZH2 have been described in chronic phase, while NF1, IDH1, IDH2, ASX1...
متن کاملPrevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran
Background and Objective: Janus kinase 2 (JAK2) and Myeloproliferative Leukemia (MPL) mutations are confirmatory indicators for Myeloproliferative Neoplasm (MPN). The current study was performed to determine the frequency of MPL mutation in MPN patients without JAK2 mutation, in order to assign MPL mutation frequency in North-East of Iran.Methods: Total o...
متن کاملCombination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway.
Human urinary bladder cancer is the fifth most common cancer, with a worldwide estimate of about two million patients. Recurrence after complete transurethral prostatic resection is the most important problem in therapy. Combination therapy is a new approach in the treatment of cancers that do not respond to current therapies. These therapies have many advantages over conventional therapies, su...
متن کاملR723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
The activating mutations in JAK2 (including JAK2V617F) that have been described in patients with myeloproliferative neoplasms (MPNs) are linked directly to MPN pathogenesis. We developed R723, an orally bioavailable small molecule that inhibits JAK2 activity in vitro by 50% at a concentration of 2nM, while having minimal effects on JAK3, TYK2, and JAK1 activity. R723 inhibited cytokine-independ...
متن کاملQuinazoline derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR /p70s6k signaling pathway
Objective(s): We previously reported a series of quinazoline derivatives as vascular-targeting anticancer agents. In this study, we investigated the mechanism underlying the anti-angiogenic activity of the quinazoline derivative compound 11d. Materials and Methods: We examined the effects of quinazoline derivative 11d on vascular endothelial growth factor receptor-2 (VEGFR2) activation via VEG...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Tropical Journal of Pharmaceutical Research
سال: 2023
ISSN: ['1596-5996', '1596-9827']
DOI: https://doi.org/10.4314/tjpr.v22i6.2